NCT04565275: A Study of ICP-192 in Patients With Advanced Solid Tumors

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for phase 1 of the study
Exclusions: Patients with prior treatment of elective pan-FGFR molecular inhibitors or antibody drugs, except for the FGFR4 selective inhibitors; Patients with known central nervous system metastases

Comments are closed.

Up ↑